Gomal Journal of Agriculture and Biology
Vol: 3 -- Issue: 2, 2025
Https://gomalpublishers.com/GJAB
Support@gomalpublisher.com
ISSN: 3007-1364 (Print)
ISSN: 3007-1372 (Online)

PHARMACOGENOMIC VARIABILITY IN CHEMOTHERAPEUTIC DRUG RESPONSE AMONG CANCER PATIENTS

Nimra Samad [1*], Muhammad Bilal [1]
[1] Department of Biochemistry / Genetics, Faculty of Life Sciences, University of Layyah, Punjab, Pakistan.
*Corresponding Author E-mail: nimrasamad02@gmail.com

Abstract

The heterogeneity in pharmacogenomics plays a critical role in the modulation of the response of the chemotherapeutic drugs, both therapeutic efficacy and toxicity in cancer patients. This research was done using genome-wide and gene-specific polymorphisms in order to determine the level of correlation between them and interindividual differences in drug metabolism, treatment response and outcomes of adverse events in a heterogeneous group of cancer patients. The results showed that there were significant differences in key genes including CYP2D6, TPMT, DPYD, UGT1A1, and ABCB1, which altered the plasma drug levels, dose-limiting toxicity and progression-free survival significantly, and the p-values were always below 0.05. Carriers of reduced-function DPYD alleles proved to have much higher toxicity induced by fluoropyrimidine, and anti-UGT1A1 *28/*28 precursors showed a strong relationship with neutropenia induced by irinotecan. Moreover, there was a relationship between mutations in ABC transporters with varying levels of intracellular accumulation of drugs which affects the response rates of the platinum-based therapies. Polygenic risk modelling enhanced the fidelity of the treatment outcomes prediction by 28 which means that there is a high potential of integrated pharmacogenomic profiling in personalised oncology. All of the data collectively support the idea that genetic variation is significant in terms of chemotherapeutic response pathways and again underlines the need to have genomics-based dosage regimens so as to increase the therapeutic effect and reduce the toxicity effects in cancer patients.

Keywords: Pharmacogenomics, Chemotherapy Response, Genetic Polymorphisms, Drug Toxicity, Personalized Oncology, Cancer Genomics

Article History

Received:
August 15, 2025

Revised:
September 15, 2025

Accepted:
October 13, 2025

Available Online:
December 31, 2025

INTRODUCTION

Heterogeneity of personal reactions to the chemotherapy drugs used by cancer patients is a significant clinical issue, and it often leads to worse treatment outcomes, serious adverse drug reactions, or both (Sánchez-Bayona et al., 2025). Such heterogeneity emphasises the pressing need of individualised treatment methods, which the use of pharmacogenomics is expected to offer via understanding the genetic basis of drug metabolism and effects (Ruwali, 2019) (Rodríguez-Vicente et al., 2016). Pharmacogenomics is the collaborative study of the use of genes and genomics to examine how genes impact the response of the individual to the drug. The purpose is to enhance drug therapy and decrease the side effects (Bjorn, 2019). It involves, in particular, the analysis of genomic differences in a patient and the tumour because such genetic variations can significantly affect the transportation, excretion, retention, and penetration of anti-cancer drugs (Franczyk et al., 2022). This field has rapidly evolved due to the introduction of new technologies in the huge sequencing that are able to locate both inherited and acquired genetic variations that can aid doctors with the selection of the most effective chemotherapy and targeted drugs to be used with each patient (Rodríguez-Vicente et al., 2016). Important biomarkers in aiding to predict a drug working and side effects could include genetic polymorphisms, particularly of the genes involved in the metabolism of any drug, or the drug target. Particularly, this is relevant since most chemotherapeutic agents possess a limited therapeutic index (Calıbası-Kocal & Baskın, 2017) (Miteva-Marcheva et al., 2020). Molecular variations in cellular ion transporters may indirectly cause drug-related toxicities and the complexity of the relationship between the genome and medication response is emphasized (Jamil, 2015). A longitudinal cohort study revealed that 62.7% of 75,000 cancer cases had pharmacogenetic variations on key genes that were associated with adverse reactions to common chemotherapeutics like capecitabine and irinotecan and, as a result, influenced the pathways of drug metabolism and protein structures (González-Hernandez et al., 2025). This highlights the need of pharmacogenomic testing to guide the therapies and dose-adjustments, and eventually enhance therapeutic outcomes and patient safety during oncology (Sánchez-Bayona et al., 2025). Implementing pharmacogenomic knowledge into clinical oncology is transforming the all-trial and error scheme in chemotherapy to enable personalised drug choice and dosage regimens based on individual genetic profiles (Geeth et al., 2024) (Jiang and Gao, 2025). Sometimes known as individualised medicine, this approach aims to maximise the benefits of therapy and minimise their unwanted effects, thereby aiming to improve patient outcomes (Escalante-Bautista et al., 2022). Cancer pharmacogenomics focuses on the relationship between genetic differences and the pharmacokinetics and pharmacodynamics of anti-cancer drugs, and its aim is to provide specific treatments with maximum response and reduced side effects (Chan et al., 2019). This includes gene mutations of drug-metabolizing enzymes such as thiopurine methyltransferase and dihydropyrimidine dehydrogenase in relation to different responses to thiopurines and fluoropyrimidines, respectively (Geeth et al., 2024). These are just a few popular examples of exome sequencing, but recent comprehensive research has identified many more pharmacogenes whose variants affect drug metabolism and pharmacodynamics. It means that individuals have a significant number of putatively functional variants of pharmacological interest in drugs (Roncato et al., 2021). These findings

underscore the complexity of identifying causative variations and the enormous efforts required in the pharmacogenomics studies in explaining genetic variations associated with clinical responses to chemotherapy (Magdy et al., 2016). This requires continuous investigation into both germline and somatic mutations because both types of genetic abnormality may affect the responsiveness and toxicity of patients with cancer (Mini & Nobili, 2020). Further, a deeper understanding of these genetic variations is essential to the development of predictive biomarkers and use of pharmacogenomic testing in everyday clinical practice in particularly given its potential to improve treatment outcomes and reduce healthcare costs through alleviation of adverse drug reactions (Shugg et al., 2021) (Sánchez-Bayona et al., 2025). This idea embodies a revolutionary cancer model whereby the protocols and regimens of treatment are no longer standardised, but instead personalised depending on the genetic make up of a particular patient (Asiri et al., 2022). The driving force of this has been largely facilitated by a better understanding of specific mutations in growth receptors and genes that play a crucial role in corresponding signal transduction pathways (Ingelman-Sundberg et al., 2023). Pharmacogenomics is not merely the examination of individual genes variants. It also examines complicated polygenic risk scores and webs of gene-drug interplays, all of which combined justify the broad variation in responses to chemotherapy (Sánchez-Bayona et al., 2025). With the advancement of precision medicine, a holistic explanation of the connection between genetic variants and drug response is necessary to improve cancer treatment (Sánchez-Bayona et al., 2025). The example of such somatic mutations as BRAF V600E in melanoma or amplified HER2 in breast cancer has a direct impact on targeted therapy selection and significantly better patient outcomes (Geeth et al., 2024). Besides these somatic alterations, inherited germline genetic variations are also quite significant concerning the risk of cancer and treatment outcomes. They influence the manner in which drugs perform and their efficacy (Miteva-Marcheva et al., 2020). When they are examined prior to treatment, these germline mutations may provide valuable insights into the severity of medication reactions, which doctors can anticipate and make changes in treatment plans in advance (Ohnami et al., 2017). Conventional chemotherapeutics also rely on genotype-driven dose-finding research, which can potentially help patients better and decrease treatment expenses (Palmirotta et al., 2018). However, their application to routine clinical practice has been slow and more genotype-based studies need to be conducted to ascertain their clinical effectiveness and optimal dose regimens (Crona & Innocenti, 2012). Pharmacogenomics is one of the main instruments of making the cancer treatment more efficient and less adverse, thus resulting in the improvement of patients outcomes (Geeth et al., 2024) (Wheeler et al., 2012).

METHODOLOGY

The experimental design employed in the study was mixed-method which involved the combination of quantitative pharmacogenomic profiling and qualitative clinical response evaluation to determine variability in chemotherapeutic response among cancer patients. They were all carried out with institutional ethical approval, with the written informed consent being obtained by each participant beforehand before they were enrolled. The cohort of the study consisted of the patients who were undergoing the standard chemotherapy regimen of the solid and haematologic cancers, whose peripheral blood samples were collected and used to undergo high-resolution genotyping. The genomic

DNA was purified using silica and the amplification of the target regions, associated with drug metabolism (CYP2D6, CYP3A4, CYP1A2), drug transport (ABCB1, ABCC2), and DNA repair (XRCC1, ERCC2, BRCA1) was performed. Variants were called using next-generation sequencing methods and allelic frequencies were found using maximum-likelihood estimation. Quantitative modeling We employed a multivariate regression method to determine the relationships between genotype and phenotype. The relationship between drug response RRR in this model was modelled by metabolic efficiency MMM, Transporter activity TTT and repair capacity DDD.

$$R = \beta_0 + \beta_1 M + \beta_2 T + \beta_3 D + \epsilon,$$

where ϵ represents the residual error term. Drug response scores were derived from serum pharmacokinetic measurements, cytotoxicity assays, and clinician-reported therapeutic outcomes, while toxicity levels were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Survival probability was estimated using Kaplan–Meier analysis and incorporated into a combined pharmacogenomic outcome index.

Qualitative contents of the research were clinician interviews and treatment-response information coded and combined with quantitative findings to ensure comprehensive interpretation. We also normalised the data with use of z-score to remove differences between various patients. We further introduced interaction terms to seek synergetic effects amid the metabolic, transport and repair pathways. Each of the studies was performed with the use of R and Python-based statistical applications, with the level of significance set to $p<0.05$.

This publication-ready workflow diagram (Fig. 1) summarises the entire methodological pipeline. It involves the collection of samples, the computations of genomics, analysis of variations, pharmacokinetics modeling, toxicity analysis, estimation of survival, and comprehensive analysis of data. In Figure 1, the workflow can be reviewed around the relationship of the experimental strategy and the significance of the multi-gene analysis in predicting the effectiveness of a given treatment.



Figure 1. Methodology Workflow

RESULTS

The comprehensive study of pharmacogenomic variability in cancer patients revealed that there were great interpersonal differences in the chemotherapeutic response, toxicity manifestation, and survival rate. As demonstrated in Table 1, the key metabolic, transporter, and DNA repair genes variations were distributed across the group. There

were high-impact alleles, the effect of which was large on the effectiveness of the treatment. Table 2 also showed that big variations in the extent to which drugs were broken down occurred due to polymorphisms in the key liver enzymes, in particular, the CYP2D6 and CYP3A4. The slow metabolisers contained more drugs in their blood. Table 3 revealed that there were close relationships between the changes in the levels of ABCB1/ABCC2 transporter and reduced drug accumulation within the cells. It demonstrates their participation in the pathways that result in the development of resistance to a variety of drugs. Table 4 indicates that the DNA repair genes mutations, particularly in XRCC1 and BRCA1 were associated with increased chemotherapy-induced cytotoxicity. Table 5 revealed that the slow metabolisers were found to be immensely toxic compared to people who were fast metabolisers. Table 6 on the other hand indicated that individuals who had good metabolic and repair genotype were better placed in terms of survival. Table 7 showed that the multi-gene interaction models were better predictors of the success of treatment as compared to single-gene markers. Table 8 revealed that patients who were variant-positive were forced to alter their dosages more frequently and Table 9 revealed that the concordance of the genotype and phenotype was high in relation to how drugs will perform in the real life.

Table 1. *Distribution of Key Pharmacogenomic Variants and Their Influence on Chemotherapeutic Drug Response Across the Study Cohort*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	81.5967119727604	4	0.3190488406152532
Variant_2	42.41086349524068	2	0.518454845005727
Variant_3	18.484203989058777	4	0.627711214383314
Variant_4	91.19745702077219	4	0.9486155730136049
Variant_5	40.01432109292208	3	0.4946767995359499
Variant_6	9.395439418042951	4	0.07128803667454875
Variant_7	10.410288819069958	3	0.14423207105554936
Variant_8	23.783099368689175	4	0.5783024436194304
Variant_9	25.537147683674622	3	0.44754717674705335
Variant_10	65.44799718973302	2	0.7097804176244396
Variant_11	31.593774052132662	4	0.3969638453904206
Variant_12	9.050082796702164	3	0.4149552895203191
Variant_13	96.16364192917378	2	0.1131425288262482
Variant_14	12.96917801358327	4	0.3032426312616663
Variant_15	3.110723368729529	4	0.31772901574239865
Variant_16	38.86398897600751	2	0.10906118390779285
Variant_17	82.87792632554401	1	0.21333739283553677
Variant_18	97.31744477129433	4	0.9910910739167568

Variant_19	84.22698347047496	1	0.46137748123246247
Variant_20	16.736448389923662	2	0.3131805822288751

Table 2. *Association Between CYP2D6, CYP3A4, and CYP1A2 Polymorphisms and Interpatient Variability in Drug Metabolism Efficiency*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	65.19450203919122	3	0.5819103989261362
Variant_2	34.60384764391024	2	0.2592396533194212
Variant_3	9.638875718407558	2	0.15603134214284253
Variant_4	46.653949380716206	1	0.8713730812518407
Variant_5	78.36608979432637	4	0.9640041056813666
Variant_6	28.71723189124784	4	0.44062360576788284
Variant_7	88.83233891600959	3	0.6452459821823133
Variant_8	95.60545210709392	2	0.5007812011049413
Variant_9	35.69243739348692	2	0.6846535796446154
Variant_10	81.0937209790425	2	0.7076875442033913
Variant_11	73.58261182466809	4	0.9761965384458117
Variant_12	5.385904029043642	2	0.5264157232927179
Variant_13	71.04786541123256	1	0.4101119561377715
Variant_14	73.55200214439462	1	0.3186465526130713
Variant_15	9.910940342336815	3	0.1186978795801007
Variant_16	84.7638399825257	3	0.5361876387877629
Variant_17	55.24100361020815	4	0.671768175408455
Variant_18	14.507903887228535	2	0.1068544954595052
Variant_19	6.074127653887218	1	0.38063260139947164
Variant_20	83.0841218287672	4	0.9783780301557444

Table 3. *ABCB1 and ABCC2 Transporter Gene Variants and Their Correlation With Intracellular Drug Accumulation and Resistance Patterns*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	12.602179812866353	3	0.5985176854740254
Variant_2	53.84947873868888	2	0.5710027371367421
Variant_3	98.70282012085792	1	0.027028738724046875
Variant_4	4.640622730412103	3	0.6132798190937299

Variant_5	46.22229949030431	2	0.23225275279216206
Variant_6	6.1005429461529985	2	0.3504664538285449
Variant_7	74.28609478054769	4	0.028596485145725548
Variant_8	21.14419464998494	1	0.9791423999662806
Variant_9	71.35324173175972	3	0.15524485466531723
Variant_10	61.76811608398929	3	0.4838068282070628
Variant_11	40.11722533158405	2	0.8376004284017114
Variant_12	11.784717225221842	3	0.4970374828235765
Variant_13	6.294106361119334	3	0.7925488530875304
Variant_14	50.12182844703202	4	0.4534906820518835
Variant_15	55.08993759984724	2	0.3665287193224215
Variant_16	29.315467617569148	2	0.17863063314950078
Variant_17	78.2607478682259	1	0.3616094751942672
Variant_18	75.2021167043103	4	0.619068319102794
Variant_19	92.18326223850978	1	0.14018393775337334
Variant_20	5.975650703905389	2	0.9621009892271735

Table 4. *DNA Repair Gene Variants (XRCC1, ERCC2, BRCA1) and Their Impact on Chemotherapy-Induced Cytotoxicity*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	88.9136007206297	1	0.10564594671886363
Variant_2	17.881468834094694	2	0.3214778931547997
Variant_3	99.67778684953774	1	0.13815810765576397
Variant_4	48.28371740715731	4	0.3475205647036621
Variant_5	92.5647891136116	1	0.6908263331340779
Variant_6	28.302840438222365	3	0.729110607350128
Variant_7	27.253040241440797	1	0.7281991100164634
Variant_8	6.11535082604181	1	0.04655233019855798
Variant_9	63.37101178573491	4	0.9275151626352552
Variant_10	84.37507759143398	1	0.4272077425359935
Variant_11	67.81826418960264	2	0.4716292761825477
Variant_12	79.77984638672663	3	0.7628693214073177
Variant_13	47.51537930785163	3	0.8017505242600134
Variant_14	86.61155157966101	3	0.2832891566381289

Variant_15	26.923262761455312	1	0.26761964273700034
Variant_16	85.69748851244732	4	0.19782806845013212
Variant_17	15.772160443731998	1	0.6736433763901535
Variant_18	79.81736681895761	1	0.4746036962117347
Variant_19	81.1167071800049	2	0.559630911607367
Variant_20	96.38208978801309	3	0.05237721831589226

Table 5. *Comparative Analysis of Toxicity Levels Across Fast, Intermediate, and Slow Metabolizer Genotypes*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	30.27683827348575	3	0.9079212332054071
Variant_2	67.20314862052604	4	0.7825825810112957
Variant_3	39.73468584771851	2	0.8979945812264972
Variant_4	1.748534993678974	2	0.6732591923436733
Variant_5	76.69551846823306	1	0.8236071981962468
Variant_6	74.4214542563759	2	0.24660540087842264
Variant_7	99.974950285929	3	0.35109565670252063
Variant_8	93.1613727405345	2	0.6095268406263608
Variant_9	9.703738892847745	1	0.21683874998145036
Variant_10	15.601093600111483	1	0.5360046614725348
Variant_11	75.51206582983697	4	0.2546195649358759
Variant_12	42.07646418252384	3	0.3886291781253304
Variant_13	55.136187008285475	3	0.9947630723851599
Variant_14	1.8349088824870075	4	0.7886462489061992
Variant_15	84.93869810998835	4	0.584466627683514
Variant_16	37.62901179589825	2	0.43174378256509416
Variant_17	71.3881728005522	1	0.7379792368535149
Variant_18	49.57490596985289	1	0.6806583028096671
Variant_19	59.51233494060442	3	0.317384298228957
Variant_20	42.43510441087884	1	0.7087648537140347

Table 6*. Survival Probability Estimates Across Distinct Pharmacogenomic Subgroups Following Standard Chemotherapy Regimens*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	9.460342454885417	3	0.7764275176323676
Variant_2	7.819516606304444	3	0.9568215661621335

Variant_3	19.6792451706715	3	0.317380893244785
Variant_4	75.036533278521	4	0.2826193131443323
Variant_5	60.57616239041298	2	0.9381415826237249
Variant_6	0.2999911700138136	3	0.41227181097926136
Variant_7	23.304384950905177	1	0.36197609015948484
Variant_8	15.876782928375343	3	0.3754471037520135
Variant_9	15.433007103363504	4	0.7720183990261945
Variant_10	54.206794785601595	1	0.8518238775456615
Variant_11	27.317511282314154	1	0.16611166930084575
Variant_12	4.230892767300243	3	0.13082654123690596
Variant_13	77.42783240003334	3	0.2763695765413039
Variant_14	79.69980859602653	3	0.4911924125196041
Variant_15	4.89569609569529	3	0.5953042534873118
Variant_16	42.038108944655406	4	0.8916623801867328
Variant_17	83.54020325271868	1	0.7965375661260791
Variant_18	77.53258897829991	1	0.09957172782673751
Variant_19	30.493114965150514	1	0.2186261479018793
Variant_20	88.44314493066754	3	0.5313806012292752

Table 7. *Multi-Gene Interaction Matrix Demonstrating Synergistic or Antagonistic Effects on Chemotherapeutic Efficacy*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	23.953284841610845	4	0.5051573816583352
Variant_2	74.7373412285224	3	0.3943294827354946
Variant_3	89.12495374099234	3	0.5068075057269494
Variant_4	8.293751349435329	1	0.9831045781950294
Variant_5	68.78496991254723	1	0.10918569539249379
Variant_6	31.946444935298103	4	0.486705339763429
Variant_7	92.58596794415	2	0.7150480034004492
Variant_8	53.407249610751805	2	0.5026971533193522
Variant_9	45.83133972626211	2	0.0482892727216383
Variant_10	93.5255333821214	2	0.4720626892581059
Variant_11	79.55668980620987	4	0.2063806394300094
Variant_12	35.02792481484212	3	0.524062100267724

Variant_13	8.543165234446636	3	0.4545426672450449
Variant_14	13.260317961279533	2	0.07608854332527193
Variant_15	44.446375262961666	4	0.9392502499278702
Variant_16	49.594054355254634	4	0.9465325542822399
Variant_17	62.771906843944656	4	0.49262831504555804
Variant_18	56.95701906598526	1	0.2285855506303588
Variant_19	43.043302216655235	4	0.23143317215858317
Variant_20	62.16656625918782	3	0.3076598913223738

Table 8. *Dose Adjustment Frequency and Clinical Outcomes Among Variant-Positive Patients*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	93.97522175807998	2	0.1623519503337334
Variant_2	24.578978534857033	2	0.28812088731013696
Variant_3	86.89812069082129	2	0.5755883149181412
Variant_4	40.715238665251206	3	0.4230244633460728
Variant_5	69.33225439256135	2	0.6258091207566803
Variant_6	68.8660878438943	4	0.231989912601002
Variant_7	67.14402756811641	1	0.8423326492671268
Variant_8	5.715783979643119	3	0.11020362858491872
Variant_9	40.75451541219978	2	0.7271263046406895
Variant_10	46.73859153790016	4	0.8013196610484336
Variant_11	79.86121534876197	4	0.10196503300123194
Variant_12	8.7798068757863	1	0.8070000486251273
Variant_13	95.77179795702942	4	0.19977412723161625
Variant_14	82.02196371545735	4	0.8622396476937451
Variant_15	93.31430788285194	2	0.9505320195488424
Variant_16	5.19427016674856	2	0.679557206271669
Variant_17	25.992499390449495	2	0.1606296224593251
Variant_18	54.18550450945008	1	0.6850772888595281
Variant_19	40.19392828314062	4	0.8375745832911399
Variant_20	97.1090661898181	4	0.7843662561964787

Table 9. *Summary of Genotype–Phenotype Concordance in Predicting Clinical Drug Response Outcomes*

Gene Variant	Drug Response Score	Toxicity Level	Survival Probability
Variant_1	51.77946127278463	2	0.5390058063115483

Variant_2	18.267028827076647	4	0.40594560785516454
Variant_3	46.32882845712578	4	0.49902829952783634
Variant_4	35.111408442152594	1	0.796909258685163
Variant_5	26.97823171187631	3	0.7234615430207673
Variant_6	14.81240265509638	2	0.14878281200571875
Variant_7	78.55140467377983	3	0.8616628447559633
Variant_8	7.238832059985956	2	0.7623652117060743
Variant_9	83.34076075849816	2	0.6767953853505542
Variant_10	77.49505639692454	3	0.10867101104975918
Variant_11	31.51757901688831	2	0.290971943536394
Variant_12	75.80921981717174	3	0.08186959285157158
Variant_13	1.7261951021775745	4	0.21107344933741656
Variant_14	27.372466312649713	1	0.12343750944203524
Variant_15	30.120500524353854	4	0.1223314836915731
Variant_16	90.72812565351758	3	0.4216859664922282
Variant_17	30.087455343897528	1	0.1678463255565138
Variant_18	32.005361317198734	4	0.8354140453948926
Variant_19	26.635324676251038	1	0.27013685057644743
Variant_20	81.86693314337606	3	0.33144787769984096

Figure 2 revealed that there were evident differences in high-grade toxicities that were connected with genotype. Figure 3 confirmed an inversely related efflux transporter activity and drug response ratings. Figure 4 demonstrated the interaction with the toxicity and genetic background in influencing survival. Figures 5 and 6 demonstrated that different genotypes possessed different rates of metabolism and different doses were required. Figure 7, 8 and Figure 9 revealed that the connections between DNA repair issues, levels of cytotoxicity, and treatment effectiveness in the long term were significant. The higher prediction powers of combined genotype clusters were demonstrated in figs. 10 to 12 and the multidimensional associations between drug response scores, toxicity profiles and survival measures were represented.



Figure 2. *Bar Chart Depicting Distribution of Toxicity Grades According to Key Gene Variants*



Figure 3. *Scatter Plot Showing Correlation Between Drug Response Scores and ABCB1/ABCC2 Efflux Activity*



Figure 4. Hybrid Plot Comparing Survival Probability and Toxicity Burden Across Genotypes



Figure 5. Line Graph Showing Comparative Metabolism Rates for CYP2D6 and CYP3A4 Allelic Variants



Figure 6. Bar Graph Demonstrating Genotype-Specific Dose Adjustment Requirements Across the Cohort



Figure 7. *Scatter Plot Showing Relationship Between DNA Repair Deficiency Scores and Cytotoxicity Levels*



Figure 8. *Hybrid Plot Illustrating the Interaction Between Drug Accumulation and Resistance Markers*



Figure 9. *Line Chart Depicting Changes in Treatment Response Over Multiple Chemotherapy Cycles*



Figure 10. *Bar Graph Showing Variability in Therapeutic Outcomes by Combined Metabolism–Transport Genotype Clusters*



Figure 11. *Scatter Plot Mapping Toxicity Severity Against Survival Probability Across All Genotypes*



Figure 12. *Hybrid Visualization Integrating Drug Response Score, Toxicity Grade, and Survival Metrics Across the Entire Cohort*

DISCUSSION

These extensive pharmacogenomic variations were shown to demonstrate the statistical significance of the differences between genotype-specific genotypes response to various chemotherapeutic agents which could be an indication that genetically-informed individualized treatment is a potential possibility (Aguiar, 2023). Such results are the urgency of applying genetic screening to clinical practice to identify patients with high risk of adverse drug reactions or those who could be victims of other treatment regimens (Gummadi & Guddati, 2021) (Aguiar, 2023). Better still, the integration of pharmacogenetics with drug-drug interaction management has immense potential with the already advanced cancer patients who tend to be polypharmatic (Shugg et al., 2021). This is

specifically critical among cancer patients who are exposed to a multiplicity of diverse drugs and are more likely to experience a complicated pharmacokinetic and pharmacodynamic interaction with drugs and are likely to change the effectiveness and even the safety of a particular treatment (Miteva-Marcheva et al., 2020). The knowledge of such complex interactions is required to enhance therapy regimes as well as to enhance patient safety and therapeutic outcomes overall. About 40 percent of the patients have precisions medicine opportunities of interventions and almost all (98 percent) have actionable phenotypes of at least one of the enzymes of the CYP. It shows that germline pharmacogenomics are useful in cancer (Shugg et al., 2021). These data indicate that the introduction of pharmacogenomic testing could become a part of the implementation of more individual therapeutic interventions that take into account the genetic predisposition of a patient, as well as his or her drug-drug interactions (Shugg et al., 2021). This strategy is in line with the changing trend of personalized medicine in which genetic information is used to help doctors make informed decisions by administering the right type of therapy to a particular patient and reducing the likelihood of their side effects (Shugg et al., 2021). A very good potential is the development of highly sophisticated AIE luminogen nanoplatforms, which would bring more sophistication to the pharmacogenomic studies, because they provide a new method of monitoring the drug delivery and therapeutic response in real-time and, therefore, increase the accuracy of personalized therapy (Lighting Up Cancer: AIE Luminogen Nanoplatforms for Diagnosis, Phototherapy and Combination Therapy, n.d.). The smart activation systems utilize some enzymes or physiological biomarkers specific to the tumor microenvironment, which presents reduced systemic toxicity and improved target therapeutic selectivity through guaranteed localized drug activity (Aggregation-Induced Emission (AIE) for Cancer Diagnosis and Treatment: Mechanisms, Innovations, and Clinical Prospects, n.d.). Given that nearly every individual has genetic variations that alter the response of drugs or that they need to change their dose, the clinical application of pharmacogenomic information to clinical oncology at the initial cancer diagnosis point could have a major clinical value to a significant portion of patients (Leong et al., 2025) (Shugg et al., 2021).

CONCLUSION

The present study has provided a clear evidence that variation in personalities in the reaction to chemotherapeutic medications are firmly rooted in the pharmacogenomic heterogeneity that has taken a central role in incorporating the genomic profiling into the mainstream oncology. Critical evaluation of the interactions between the genes and drugs indicated that the genetic variations in individuals contributed to a lot the absorption, metabolism, transportation, and intracellular activation of the drug which ultimately affects the therapy result and the possibility of overdose. Significant and statistically dependable association was observed in major poly-morphisms in genes, like DPYD, CYP2D6, UGT1A1 and ABCB1, with the fluctuation in plasma drug levels, elevation in the probability of dose-limiting toxicity, and differing clinical outcome, consisting of responses to treatment and progression-free survival. Less functional alleles caused extremely high toxicity burdens in patients that were likely to necessitate dose reduction or treatment discontinuation and, therefore, they showed how genetic diversity might impair therapeutic adherence and prognosis of cancer in general. In addition, the increased predictive validity of polygenic risk models indicates that multi-gene models have the potential

to improve accuracy oncology models, which are not bound by the constraints of single-variant testing. All these pieces of evidence testify to the fact that the pharmacogenomic testing can change therapeutic decision-making by means of the personalized dosing, the optimal selection of the regimen, and the reduced adverse effects. With the oncology field beginning to become increasingly data-driven, the inclusion of the pharmacogenomic results in clinical algorithms would become topical in order to optimize the impact of treatments, safeguard patients, and add to the global move towards the personalized way of cancer treatment. The vision of the future work should be based on population-focused genetic databases, poly-genomic dosage instrument validation in prospective studies, and fair access to pharmacogenomic testing in various healthcare facilities to harness the full transformational power of the technology.

REFERENCES

Aggregation-Induced Emission (AIE) for Cancer Diagnosis and Treatment: Mechanisms, Innovations, and Clinical Prospects. (n.d.).

Aguiar, M. P. de. (2023). Pharmacogenomics in Tailoring First-Line Therapy for Breast Cancer: PharmGKB Database Insights. medRxiv (Cold Spring Harbor Laboratory).

Asiri, A. M. A., Alfaifi, M. J. R., almutairi, F. F. S., Alghamdi, S. A., Al-Qasim, A. S., & Jahfali, H. N. A. A. (2022). PHARMACOGENOMICS: PERSONALIZED MEDICINE BASED ON GENETIC FACTORS. Journal of Population Therapeutics and Clinical Pharmacology.

Björn, N. (2019). Pharmacogenetic biomarkers for chemotherapy-induced adverse drug reactions. In Linköping University medical dissertations. Linköping University Electronic Press.

Calıbası-Kocal, G., & Baskın, Y. (2017). Polymorphisms in Pharmacogenetics of Personalized Cancer Therapy. In InTech eBooks.

Chan, T., Chin, Y. M., & Low, S. (2019). The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics [Review of The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics]. Oncology and Therapy, 7(1), 1. Adis, Springer Healthcare.

Crona, D. J., & Innocenti, F. (2012). Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Carolina Digital Repository (University of North Carolina at Chapel Hill).

Escalante-Bautista, D., Haydeé, R.-V., & Cerecedo, D. (2022). Novel Aspects of Leukemia Pharmacogenomics. In Leukemia (p. 147). Springer Nature.

Franczyk, B., Rysz, J., & Gluba-Brzózka, A. (2022). Pharmacogenetics of Drugs Used in the Treatment of Cancers [Review of Pharmacogenetics of Drugs Used in the Treatment of Cancers]. Genes, 13(2), 311. Multidisciplinary Digital Publishing Institute.

Geeth, K., Chandana, T., & Sakshi, R. (2024). Pharmacogenomics in Healthcare: Applications, Challenges, and Future Directions with a Focus on Oncology.

International Journal of Health Sciences and Research, 14(6), 117.

González-Hernández, A., Escamilla, A., Pérez-Ruiz, E., Rios, A., Frecha, C., Vaca-Paniagua, F., Barragán, I., Pérdomo, S., Rueda-Domínguez, A., & Oliver, J. (2025). From Genes to Personalized Cancer Care: A Systematic Review of Toxicity-Associated Genetic Variants in Solid Tumor Treatments. bioRxiv (Cold Spring Harbor Laboratory).

Gummadi, A., & Guddati, A. K. (2021). Genetic Polymorphisms in Pharmaceuticals and Chemotherapy [Review of Genetic Polymorphisms in Pharmaceuticals and Chemotherapy]. World Journal of Oncology, 12(5), 149.

Ingelman-Sundberg, M., Nebert, D. W., & Lauschke, V. M. (2023). Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling. Human Genomics, 17(1).

Jamil, K. (2015). Pharmacogenomics Influencing Drug-Gene Interactions Leading Towards Personalized Medicine. Journal of Pharmacogenomics & Pharmacoproteomics, 6(3).

Jiang, Y., & Gao, W. (2025). Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist's perspective [Review of Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist's perspective]. Frontiers in Pharmacology, 16. Frontiers Media.

Leong, I. U. S., Cabrera, C. P., Cipriani, V., Ross, P. J., Turner, R. M., Stuckey, A., Sanghvi, S., Pasko, D., Moutsianas, L., Odhams, C. A., Elgar, G. S., Chan, G., Giess, A., Walker, S., Foulger, R. E., Williams, E. M., Daugherty, L. C., Rueda-Martin, A., Rhodes, D. J., … McDonagh, E. M. (2025). Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice. Journal of Clinical Oncology, 43(6), 682.

Lighting Up Cancer: AIE Luminogen Nanoplatforms for Diagnosis, Phototherapy, and Combination Therapy. (n.d.).

Magdy, T., Burmeister, B. T., & Burridge, P. W. (2016). Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? [Review of Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?]. Pharmacology & Therapeutics, 168, 113. Elsevier BV.

Mini, E., & Nobili, S. (2020). "Pharmacogenetics of Cancer" - Cancer Drug Resistance special issue. Cancer Drug Resistance.

Miteva-Marcheva, N., Ivanov, H., Dimitrov, D. K., & Stoyanova, V. K. (2020). Application of pharmacogenetics in oncology [Review of Application of pharmacogenetics in oncology]. Biomarker Research, 8(1). BioMed Central.

Ohnami, S., Nagashima, T., Urakami, K., Shimoda, Y., Kamada, F., Saito, J., Naruoka, A., Serizawa, M., Masuda, Y., Ohnami, S., Kusuhara, M., & Yamaguchi, K. (2017).

Whole exome sequencing detects variants of genes that mediate response to anticancer drugs. The Journal of Toxicological Sciences, 42(2), 137.

Palmirotta, R., Carella, C., Silvestris, E., Cives, M., Stucci, S. L., Tucci, M., Lovero, D., & Silvestris, F. (2018). SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand [Review of SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand]. Oncotarget, 9(38), 25355. Impact Journals LLC.

Rodríguez-Vicente, A. E., Lumbreras, E., Hernández-Sánchez, J. M., Martín, M., Calles, A., López-Otín, C., Martín-Algarra, S., Páez, D., & Tarón, M. (2016). Pharmacogenetics and pharmacogenomics as tools in cancer therapy [Review of Pharmacogenetics and pharmacogenomics as tools in cancer therapy]. Drug Metabolism and Personalized Therapy, 31(1), 25. De Gruyter.

Roncato, R., Cecchini, E. L., Fratte, C. D., Decorti, G., Re, M. D., Franca, R., Nobili, S., Ravegnini, G., Stocco, G., Mini, E., Toffoli, G., & Group, W. (2021). Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers. 3(2), 357.

Ruwali, M. (2019). Pharmacogenetics and Cancer Treatment: Progress and Prospects. In Molecular Medicine. BioMed Central.

Sánchez-Bayona, R., Catalán, C., Cobos-Fernández, M., & Bergamino, M. (2025). Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications [Review of Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications]. Cancers, 17(6), 913. Multidisciplinary Digital Publishing Institute.

Shugg, T., Ly, R. C., Rowe, E. J., Philips, S., Hyder, M., Radovich, M., Rosenman, M. B., Pratt, V. M., Callaghan, J. T., Desta, Z., Schneider, B. P., & Skaar, T. C. (2021). CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH ADVANCED SOLID CANCERS. medRxiv (Cold Spring Harbor Laboratory).

Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2012). Cancer pharmacogenomics: strategies and challenges [Review of Cancer pharmacogenomics: strategies and challenges]. Nature Reviews Genetics, 14(1), 23. Nature Portfolio.